Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

CIHR doubles support for clinical research

Lauren Vogel
CMAJ April 17, 2012 184 (7) E343-E344; DOI: https://doi.org/10.1503/cmaj.109-4161
Lauren Vogel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

The Canadian government will double its funding of clinical research over the next five years as part of a renewed partnership with drug companies, Minister of Health Leona Aglukkaq announced Mar. 22.

The Canadian Institutes of Health Research (CIHR) will invest up to $150 million in a collaborative research program with Canada’s Research-Based Pharmaceutical Companies (Rx&D) to fund and improve the coordination of clinical research across the country, Aglukkaq told reporters at a press conference in Ottawa, Ontario.

One of the main goals of CIHR’s renewed partnership with Rx&D will be “increasing the number of innovative health treatments and devices ... that make it to the market,” she said.

The new funding will also support implementation of CIHR’s Strategy for Patient-Oriented Research to ensure better translation of research findings into clinical practice by developing and implementing tools to support, train, recruit and retain researchers such as clinical investigators, biostatisticians, methodologists, epidemiologists, health economists and technicians (www.cihr-irsc.gc.ca/e/documents/P-O_Research_Strategy-eng.pdf).

“We are certain that greater collaboration will open up more pathways to transform research concepts into actual practices of medicine … [and] ensure the right patient receives the right medical care at the right time,” Aglukkaq said.

Figure

Federal Health Minister Leona Aglukkaq says the government’s partnership with drug companies will increase the number of “innovative health treatments and devices” that make it to market.

Image courtesy of Lauren Vogel

Launched last year, the strategy is aimed at closing gaps in Canada’s research-to-practice continuum, including:

  • “Lack of clinical investigators, methodologists such as biostatisticians, clinical epidemiologists and health economists, and other needed experts;

  • Complicated coordination of large, multi-centre clinical trials because of requirements for multiple ethics reviews by each individual institution and the lack of standardized contracts;

  • Underfunding of patient-oriented research when compared to many other countries;

  • A decentralized federation structure, making research coordination difficult;

  • Deficiencies in the development and dissemination of guidelines and their adoption into practice, despite their proven value; and

  • The limited role of patients in patient-oriented research,” according to a background statement on the strategy (www.cihr-irsc.gc.ca/e/43999.html).

Closing such gaps would be a “strong step forward” to Canada securing “a greater share of the almost $100 billion that our industry invests in research around the world,” Rx&D President Russell Williams said at the press conference.

According to Williams, Rx&D member companies have set an objective to match CIHR investments to clinical research “dollar-for-dollar.”

The pharmaceutical industry has also partnered with the federal government to accelerate reviews of alternatives to drugs currently in severe shortage across the country.

“In normal circumstances a review would take up to 6 months. In this situation, we’re looking at getting through the process in one month,” Aglukkaq said.

Moreover, the federal government has ramped up development of a “one-stop shop” reporting system for current and impending drug shortages that’s been in the offing for over a year.

Currently, health practitioners can access national data on shortages flagged by generic and brand-name drug-makers at two websites that previously reported strictly on regional supply disruptions: the Saskatchewan Drug Information Service (http://druginfo.usask.ca/healthcare_professional/drug_shortages.php) and Vendredi PM (http://vendredipm.wordpress.com). But the makeshift registries are just a “temporary step” toward a truly comprehensive drug shortage monitoring system, as they only capture supply problems flagged by industry and don’t provide information about therapeutic alternatives (www.cmaj.ca/lookup/doi/10.1503/cmaj.109-4100).

Although it’s impossible to “do away with drug shortages” completely, establishing a centralized reporting system “will allow provinces and territories and hospitals to plan ahead,” Aglukkaq said. “Whether you’re triaging or looking at alternate products ... it would allow us the time to respond to ensure that patients who need [drugs in short supply] continue to receive that care.”

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 184 (7)
CMAJ
Vol. 184, Issue 7
17 Apr 2012
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
CIHR doubles support for clinical research
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
CIHR doubles support for clinical research
Lauren Vogel
CMAJ Apr 2012, 184 (7) E343-E344; DOI: 10.1503/cmaj.109-4161

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
CIHR doubles support for clinical research
Lauren Vogel
CMAJ Apr 2012, 184 (7) E343-E344; DOI: 10.1503/cmaj.109-4161
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Is one-way masking enough?
  • XE, XD & XF: what to know about the Omicron hybrid variants
  • 5 infectious disease topics to watch
Show more News

Similar Articles

Collections

  • Topics
    • Research methods & statistics

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire